Prakt. lékáren. 2014; 10(3): 95-98

Possibilities of pharmaceutical care in the treatment of vulvovaginal candidiasis

Peter Koliba1, Veronika Příhodová2
1 Gynartis, s. r. o., Ostrava &ndash, Vřesina
2 Lékárna U sv. Antonína, Ostrava – Vřesina

Review article intended for pharmacists dealing with vaginal candidiasis (VC) in women, from the perspective of a gynecologist. Problems

with genital yeast infections are very common, especially in women. Women in many cases rather prefer to purchase OTC drug

in a pharmacy before visiting the gynecological clinic. Although in most cases VC manifested typical clinical symptoms (genital itching,

runny or curdy, local redness, swelling and rhagades), but sometimes for the correct treatment the knowledge of the “history” is not

enough. This is the biggest pitfall for a pharmacist who is unable to assess the objective clinical findings by clinical examination, as is the

case with gynecologist examination. Important notice for pharmacists is the question on the last menstrual period (LMP) or pregnancy

due to the fact that all antifungal drugs are in the first trimester of pregnancy contraindicated (with the exception of sodium tetraborate,

and certain natural products). Nevertheless, the author accepts the possibility of self-treatment of the patient and makes recommendations

for pharmacists on the correct choice of local OTC antifungal product.

Keywords: discharge, itching, vaginal candidiasis, yeast discharge, antifungal treatment of vaginal candidiasis, probiotics

Published: June 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Koliba P, Příhodová V. Possibilities of pharmaceutical care in the treatment of vulvovaginal candidiasis. Pharmacy for Practice. 2014;10(3):95-98.
Download citation

References

  1. Kestřánek J jr., et al. Problematika vulvovaginálního dyskomfortu z hlediska mezioborové spolupráce. Epidemiol. Mikrobiol. Imunol. 2008; 57(1): 23-27. Go to PubMed...
  2. Koliba P, Koliba P jr. Problematika pohlavně přenosných infekcí v současné klinické praxi. Vox pediatriae 2010; 10 (2): 18-20.
  3. Čepický P. Chronické a recidivující vulvovaginitidy. Prakt Gyn. 2004, 2: 8-9.
  4. Fait T. Vulvovaginitis - nejčastější onemocnění ženského pohlavního systému. Medi news 2004; 3(3/4): 180-181.
  5. Turčan P. Nové možnosti v léčbě vaginálního dyskomfortu. Praktické lékárenství 2012; Suppl. A, A11-A12.
  6. Turčan P. Vaginální dyskomfort a dysmikrobie - nové možnosti řešení. Causa subita 2011; 14(4): 164-168.
  7. Mašata J, Jedličková A, a kol. Infekce v gynekologii. Praha: Maxdorf 2006: 32-34.
  8. Slíva J, Fait T. Samoléčba v gynekologii. Praha: Maxdorf 2012: 49-53.
  9. Špaček J, Buchta V, Jílek P, a kol. Vulvo-vaginální dyskomfort a poruchy poševního prostředí. Praha: Grada 2013: 294-303.
  10. Fait T. Otázky intimní hygieny v ambulantní praxi. Praktická gynekologie 2007; 3: 129-131.
  11. Fait T, Dvořák V, Skřivánek A, a kol. Almanach ambulantní gynekologie. Praha: Maxdorf: 284 s.
  12. Koliba P. Probiotika z pohledu gynekologa. Med. Pro praxi 2012; 9(8, 9): 354-359.
  13. Coco A S, Vanderbosche M. Infekční kolpitida. Medicína po promoci 2000; 1(4): 75-81.
  14. Plourd DM. Praktický průvodce diagnostikou a terapii vaginitid. Prakt. Gynek. 1998; 5: 29-41.
  15. Čillíková K. Bakteriální zánět pochvy. SANQUIS 2011; 89: 74.
  16. Turčan P. Využítí itrakonazolu v léčbě recidivujících vulvovaginitid, Lékařské listy; Speciál 2010; 7: 24-26.
  17. Státní ústav pro kontrolu léčiv - databáze léčivých přípravků - dostupné z: http://www.sukl.cz/modules/medication/search.php (cit. 2014-15-05).
  18. Akhar S, Masood S et al. Efficacy of itraconazole versus fluconazole in vaginal candidiasis, J Pak Med Assoc 2012; 62(10): 1049-5102. Go to PubMed...
  19. Marchaim D, Lemanek L, et al. Fluconazole-resistant Candida albicans vulvovaginitis, Obstet Gynecol. 2012; 120(6): 1407-1414. doi: http://10.1097/AOG.0b013e31827307b2 (cit. 2014-15-05). Go to original source... Go to PubMed...
  20. Buchta V, Matula V, Kestřánek J, a kol. Je diabetes mellitus rizikový faktor poševních kvasinkových zánětů?, Čes. Gynek. 2013; 78(6): 537-544.
  21. Kalkanci A, Guzel AB, et al. Yeast vaginitis during pregnancy: susceptibility testing of 13 antifungal drugs and boric acid and the detection of four virulence factors. Med. Mycol. 2012; 50(6): 585-593. Go to original source... Go to PubMed...




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.